Clinical trials: Hereditary Transthyretin Amyloid Neuropathy
Left Ventricular Hypertrophy
Frequency of Cardiac Amyloidosis in the Caribbean's. (TEAM Amylose)
The frequency of cardiac amyloidosis among patients presenting with a so-called left ventricular hypertrophy remains unknown. This problem is especially relevant in the Caribbean's, where an amyloidosis-prone mutation of…
- Trial name
- NCT03322319
- Testing
- Tissue biopsies
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 175 people
- Sponsor
- University Hospital Center of Martinique
Transthyretin Amyloidosis
ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy
The study will investigate the stabilization effects of Tafamidis utilizing cardiac imaging cardiac magnetic resonance imaging (CMR). The investigators propose to pursue the following specific aims: 1.
- Trial name
- NCT04513600
- Testing
- Cardiac MRI
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- The Christ Hospital
Transthyretin Gene Mutations, Transthyretin Amyloidosis
Transthyretin Amyloidosis Outcome Survey (THAOS)
THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM.
- Trial name
- THAOS (NCT00628745)
- Testing
- None. Observational Study.
- Where
- 113 sites in United States, Argentina and 23 more
- Volunteers
- 6,718 people
- Sponsor
- Pfizer
Amyloidosis, Hereditary, Transthyretin-Related, Microbial Colonization
Analysis of the Instestinal Microbiome of Patients With Transthyretin Amyloidosis
Amyloidosis is a serious systemic disease. Cardiac involvement has a great impact on prognosis and can occur in its three main forms: acquired monoclonal light chain, hereditary transthyretinal and senile form.
- Trial name
- AMIAT (NCT05196594)
- Testing
- collection of stools for genetic analysis
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.
- Trial name
- NCT04153149
- Testing
- Vutrisiran, Sterile Normal Saline (0.9% NaCl)
- Where
- 121 sites in United States, Argentina and 31 more
- Volunteers
- 655 people
- Sponsor
- Alnylam Pharmaceuticals
Aortic Stenosis, Transthyretin Amyloidosis
Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis
Aortic stenosis is the most common valve disease requiring surgery in the Western world. It is defined by progressive calcification and fibrosis of the valve leaflets and restricted valve opening.
- Trial name
- PASS (NCT03352089)
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh